{"id":7477,"date":"2024-06-10T09:00:35","date_gmt":"2024-06-10T09:00:35","guid":{"rendered":"http:\/\/medexperts.pro\/?p=7477"},"modified":"2024-06-10T09:23:29","modified_gmt":"2024-06-10T09:23:29","slug":"leqembi-and-alzheimers-what-to-know-about-the-new-drug-treatment-and-benefits","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=7477","title":{"rendered":"Leqembi and Alzheimer\u2019s: What to Know About the New Drug, Treatment and Benefits"},"content":{"rendered":"
<\/div>\n

As the F.D.A. considers a new Alzheimer\u2019s medication, we asked experts how the rollout of a similar drug has gone.<\/p>\n

\n
\n
\n

Over the last three years, a new class of Alzheimer\u2019s drug, the first to treat a root cause of the disease, has set off a roller coaster<\/a> of hope and disappointment. But while these so-called anti-amyloid antibodies had a rough start<\/a>, many patients and their doctors are feeling more optimistic now that one of the medications is finally being used more widely.<\/p>\n

Lecanemab (brand name Leqembi) was given full approval<\/a> by the Food and Drug Administration in July 2023 and is currently the only one of its class available to Alzheimer\u2019s patients, outside clinical trials. The drug has been shown to slow the progression of the disease, but its benefits are fairly modest. It is also a burdensome therapy and has a high risk of troubling side effects.<\/p>\n

With lecanemab having been approved for nearly a year \u2014 and with a similar drug, donanemab<\/a>, being reviewed by an F.D.A. advisory committee at a meeting on Monday \u2014 The New York Times checked in with experts at three major medical centers about who\u2019s receiving lecanemab and how they\u2019re responding.<\/p>\n